• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Hutchmed China Ltd ADR (NQ: HCM )

    18.00 -0.95 (-5.01%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Hutchmed China Ltd ADR

    < Previous 1 2 3 4 5 6 7 8 Next >
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
    Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
    Via Benzinga
    Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products
    Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing... 
    Via Talk Markets
    Stocks That Hit 52-Week Highs On Thursday
    Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new... 
    Via Benzinga
    The Gift Chinese Regulators Just Gave Tech Stocks Like Alibaba And BeiGene
    Auditing issues persist for some 270 companies trading in the U.S. But they could ease. 
    Via Investor's Business Daily
    Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
    Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
    Via Benzinga
    Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework
    Via Benzinga
    Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
    As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China. 
    Via InvestorPlace
    Which Chinese Stocks Could Get Delisted? 6 Companies to Watch.
    Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way. 
    Via InvestorPlace
    The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
    Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
    Via Benzinga
    Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today?
    Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next. 
    Via InvestorPlace
    What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today
    Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM... 
    Via Benzinga
    Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat
    Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO... 
    Via Benzinga
    Chinese Stocks Are Falling: What's Going On?
    Shares of multiple Chinese companies are trading lower Thursday following reports the U.S. Securities and Exchange Commision has identified multiple US-listed ADRs as... 
    Via Benzinga
    Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble
    The SEC is calling out a several stocks for non-compliance. Could they face delisting? 
    Via Investor's Business Daily
    Hutchmed Clocks Over 50% Jump In FY21 Sales Boosted By Three Oncology Drugs, Announces CEO Transition
    Hutchmed (China) Limited (NASDAQ: HCM) reported FY21 sales of $356.1 million, up 56% Y/Y, driven by commercial progress on three in-house developed oncology drugs... 
    Via Benzinga
    Earnings Scheduled For March 3, 2022
    Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
    Via Benzinga
    Week In Review: Biopharma Deals Slow During Chinese New Year Week
    Amid a slow week, Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio is an early R&D company that was incubated by Sunshine... 
    Via Talk Markets
    58 Biggest Movers From Yesterday
    Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
    Via Benzinga
    31 Stocks Moving In Thursday's Mid-Day Session
    Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... 
    Via Benzinga
    18 Stocks Moving in Thursday's Pre-Market Session
    Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO... 
    Via Benzinga
    61 Biggest Movers From Yesterday
    Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare... 
    Via Benzinga
    Exposures Product Safety
    40 Stocks Moving In Monday's Mid-Day Session
    Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced research on COVID-19 seeking... 
    Via Benzinga
    Exposures COVID-19
    20 Stocks Moving in Monday's Pre-Market Session
    Gainers Astra Space, Inc. (NASDAQ: ASTR) rose 39.6% to $13.30 in pre-market trading after declining around 3% on Friday. Astra Space recently reported a Q3 loss of $0.06 per... 
    Via Benzinga
    Week In Review: Broncus Stages $200 Million Hong Kong IPO For Pulmonary Devices
    Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. The IPO was priced at the top end of... 
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    HUTCHMED's Lymphoma Candidate Secures Breakthrough Tag In China
    The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED (China) Limited... 
    Via Benzinga
    The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
    Via Benzinga
    Exposures Product Safety
    Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
    Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
    Via Talk Markets
    Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China
    Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (... 
    Via Benzinga
    Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
    From Epizyme, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.